FTO, an m6A RNA demethylase, is known mainly as an oncoprotein in various cancer types. FTO is now shown to act as a cancer suppressor in a subset of epithelial tumors through an interplay between epithelial-to-mesenchymal transition and Wnt signaling.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Cell 169, 1187–1200 (2017).
Meyer, K. D. & Jaffrey, S. R. Nat. Rev. Mol. Cell Biol. 15, 313–326 (2014).
Barbieri, I. & Kouzarides, T. Nat. Rev. Cancer 20, 303–322 (2020).
Huang, H., Weng, H. & Chen, J. Cancer Cell 37, 270–288 (2020).
Jeschke et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00223-7 (2021).
Li, Z. et al. Cancer Cell 31, 127–141 (2017).
Su, R. et al. Cell 172, 90–105.e23 (2018).
Yang, S. et al. Nat. Commun. 10, 2782 (2019).
Wang, X. et al. Nature 505, 117–120 (2014).
Cruciat, C.-M. Curr. Opin. Cell Biol. 31, 46–55 (2014).
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Navickas, A., Goodarzi, H. A Wnt twist in FTO’s role in cancer progression. Nat Cancer 2, 579–580 (2021). https://doi.org/10.1038/s43018-021-00224-6